Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SC0191 plus chemotherapy in advanced ovarian cancer
CTR20230966Phase 2Active
- Sponsor
- Zhikang Hongyi
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sonkibartinib in ovarian cancer, High-Grade Serous Ovarian Cancer (HGSOC), sponsored by Zhikang Hongyi. Started Aug 2023; status: active.
02
Drugs
sonkibartinib
03
Conditions
ovarian cancerHigh-Grade Serous Ovarian Cancer (HGSOC)
Beyond the preview
Go deeper on CTR20230966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230966.